

RETIMIX® is a dietary supplement based on Casperiva®, a formula of Curcumin Phospholipid (Turserin®), and Boswellia Phospholipid (Casperome®).

Curcuma-Phospholipid (Turserin®) Curcuma longa (commonly known as turmeric) is an herbaceous plant, which originates in Southeast Asia and is widely used as a spice. Curcumin is the main active substance extracted from the root of the plant Curcuma longa. Over 14000 studies published in major international scientific journals have demonstrated the anti-inflammatory and anti-oxidant properties of curcumin¹. The main limitation associated with the curcumin is its high instability; once ingested, in fact, it is rapidly degraded in the stomach and only a small proportion is absorbed at the intestinal level (low bioavailability). This low bioavailability therefore requires a high dosage to achieve a therapeutic effect, restricting its use in the clinical setting. The Curcumin Phospholipid contained in RETIMIX® is composed of molecules of vegetable origin (phospholipids from non-GMO sunflower: phosphatidylserine and phosphatidylcholine) that act as a shield to envelop the curcumin and protect it from gastric degradation. This system allows the curcumin to quickly cross the gastric barrier with an intestinal absorption of about 30 times higher than the extract or the standard formulation. Due to the characteristics described, 1 packet of RETIMIX® contains the equivalent bioavailability of 1.5 g curcumin².

Boswellia-Phospholipid (Casperome®) The Boswellia serrata, or frankincense tree, is a wooded plant that is widespread, mainly in Asia. Boswellic acids (KBA, AKBA, β BA, α B, β BA, A α BA) are the main active substances extracted from the resin produced from the trunk of the tree. Over 500 studies published in important scientific journals demonstrate the anti-inflammatory and analgesic properties of boswellic acids, in particular, AKBA^{3,4}. As is the case for the curcumin, boswellic acids have poor solubility and absorption characteristics. The Boswellia Phospholipid contained in RETIMIX®, is composed of vegetable molecules (phospholipids from non-GMO soy: phosphatidylcholine) that protect boswellic acids from degradation and allow for a higher and more consistent absorption in the intestine. In particular, AKBA has an absorption rate 4 times higher compared to the commercially-available extracts of boswellia. Furthermore, this phospholipid formulation, allows a more rapid absorption of the boswellic acids (1.5-2 hrs.) compared to the standard extracts of Boswellia⁵.

The phospholipids present in functional complexes mentioned above, phosphatidylcholine and phosphatidylserine, allow the curcumin and boswellic acids to be distributed with a greater selectivity and specificity toward the tissues, in particular, into the central and ocular nervous systems and exploiting the full extent of their therapeutic properties and reducing the daily dosage^{2,3}. The efficacy of curcuma and the boswellic acids, as formulated in Retimix, has been validated in 30 clinical studies related to inflammatory pathologies⁶⁻⁹. Curcuma and boswellic acids can indeed act at the origin and throughout the inflammatory process, controlling the symptoms associated with it¹⁰.

Indication Turmeric and boswellic acids formulated at high bioavailability, contained in RETIMIX®, are indicated in order to counteract oxidative stress caused by degenerative processes relating to age and/or in the case of conditions related to the inflammatory response.¹¹⁻¹²

Directions The recommended dose is 1-2 packets daily with meals or according to the advice of your doctor. Pour the contents of a packet into a glass, add water and mix until fully dispersed, then drink.

Packaging 20 packets

Warnings Keep out of reach of children. If you are pregnant, nursing or taking medications, consult your doctor before use. Do not use if packet seal is torn or broken. Store at room temperature. Protect from moisture. Do not exceed recommended dose.

Product branded and distributed in Italy by Eye Pharma S.p.A., Via Borghero 9, 16148, Genoa Italy.

Distributed in the USA by Eye Pharma Inc. 4770 Biscayne Blvd. Suite 400, Miami FL 33137.

Turserin® and Casperome® are trademarks of Indena S.p.A. | RETIMIX® and Casperiva® are trademarks of Eye Pharma S.p.A.

Question or comments? info@eyepharma.com - www.eyepharma.com

1. He Y, Yue Y, Zheng X, Zhang K, Chen S, Du Z. Curcumin, inflammation, and chronic diseases: how are they linked? *Molecules*. 2015 May 20;20(5):9183-213. Review. 2. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. *J Nat Prod*. 2011 Apr 25;74(4):664-9. 3. Banno, N., Akhisa, T., Yasukawa, K., Tokuda, H., Tabata, K., Nakamura, Y., Nishimura, R., Kimura, Y., Suzuki, T., 2006. Anti-inflammatory activities of the triterpenoids from the resin of *Boswellia carteri*. *J Ethnopharmacol* 107 (2), 249-253. 4. Lulli M, Cammalleri M, Fornaciari I, Casini G, Dal Monte M. Acetyl-11-keto- β -boswellic acid reduces retinal angiogenesis in a mouse model of oxygen-induced retinopathy. *Exp Eye Res*. 2015 Jun;135:67-80. 5. Riva A, Morazzoni P, Artaria C, Allegrini P, Meins J, Savio D, Appendino G, Schubert-Zsilavecz M, Abdel-Tawab M. A single-dose, randomized, cross-over, two-way, open-label study for comparing the absorption of boswellic acids and its lecithin formulation. *Phytomedicine*. 2016 Nov 15;23(12):1375-1382. 6. Shelmadine BD, Bowden RG, Moreillon JJ, Cooke MB, Yang P, Deike E, Griggs JO, Wilson RL. A Pilot Study to Examine the Effects of an Anti-inflammatory Supplement on Eicosanoid Derivatives in Patients with Chronic Kidney Disease. *J Altern Complement Med*. 2017 Aug;23(8):632-638. 7. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, Togni S, Appendino G. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. *Altern Med Rev*. 2010 8. Pellegrini L, Milano E, Franceschi F, Belcaro G, Gizzi G, Feragalli B, Dugall M, Luzzi R, Togni S, Eggenhoffner R, Giacomelli L. Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of *Boswellia serrata* extract. *Eur Rev Med Pharmacol Sci*. 2016 Jun;20(12):2695-700. 9. Franceschi F, Togni S, Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Eggenhoffner R, Giacomelli L. A novel lecithin based delivery form of Boswellicacids (Casperome®) for the management of osteo-muscular pain: a registry study in young rugby players. *Eur Rev Med Pharmacol Sci*. 2016 Oct. 10. Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumin and boswellic acids. *J Ethnopharmacol*. 1993 Mar;38(2-3):113-9. 11. Mazzolani F, Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. *Clin Ophthalmol*. 2013;7:939-45. 12. Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. *Clin Ophthalmol*. 2010 Oct 21;4:1201-6.